|
- Valproate - ALZFORUM
Background Valproate is an anti-convulsant and mood-stabilizing drug that is FDA- and EMA-approved to treat seizures, manic episodes associated with bipolar disorder, and to prevent migraine headaches It is also used off-label for other psychiatric conditions Valproate products include valproate sodium, divalproex sodium, valproic acid, and generic versions thereof Side effects include
- Alzheimers Association International Conference 2018
The last full day of the Alzheimer's Association International Conference, which ended today in Chicago, saw scientists pack a room the size of an aircraft hangar in anticipation of a late addition to the scientific program They came to see the data behind a tantalizing press release issued earlier this month, which had claimed that BAN2401, the anti-Aβ protofibril immunotherapy being
- Therapeutics | ALZFORUM
AD Target Therapy Types The two tables below organize the therapeutics within this database by therapy type and proposed target type The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U S clinical trials For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total
- International Conference on Alzheimers Disease 2009
Regarding clinical trials, the news in Vienna was mostly dire Among the trials that reported results, GSK’s Phase 3 rosiglitazone program failed, the ADCS’s valproate and DHA trials were negative, as were the Phase 2b trials of AstraZeneca’s α4β2 nicotinic acetylcholine receptor agonist AZD3480 and of a monthly implant formulation of donepezil called mimopezil The large anti-amyloid
- Accelerated Brain Volume Loss Caused by Anti-β-Amyloid Drugs: A . . .
The reduction in brain volume is seen with all the monoclonal antibodies and was seen with a BACE inhibitor and with valproate I would not call it atrophy, since atrophy implies cell loss, and we do not know that to be the case
- Citalopram Calms Agitation in Alzheimer’s, but Carries Risks
Commentators agreed that citalopram shows promise for treating agitation in AD, but said more research is needed and urged clinicians to use the drug with caution “Although the results from this study support a role for citalopram in the management of agitation in dementia, when and how to prescribe the drug so that benefits are optimized and risks minimized are not straightforward
- Aberrant excitatory neuronal activity and compensatory . . . - ALZFORUM
Valproate seemed potentially useful because it is known to affect the brain Along these lines, it could be considered that β amyloid could increase the excitability in neural networks, and reduction of that excitability could reduce the predilection for tauopathy to develop
- Therapeutics Search | ALZFORUM
NSC001 AAB-003 AADvac1 AAV-GAD AAV2-BDNF ABBV-1088 ABBV-552 ABBV-916 ABT 418 ABT-089 ABT-288 ABT-384 ABT-957 ABvac40 ACD856 Acetyl-l-carnitine HCI ACI-24 060 ACI-3024 ACI-7104 056 Acitretin ACP-204 ADEL-Y01 Aduhelm AF 102B Affitope AD02 AGB101 AIT-101 AKST4290 AL002 AL003 AL044 AL101 ALIA-1758 Allopregnanolone Alpha-Tocopherol ALX-001 ALZ-101
|
|
|